DNA amplifications in breast cancer are frequent on chromosome 11q, in which multiple driver oncogenes likely reside in addition to cyclin D1 (CCND1). One such candidate, the scaffolding adapter protein, GRB2-associated binding protein 2 (GAB2), functions in ErbB signaling and was recently shown to enhance mammary epithelial cell proliferation, and metastasis of ERBB2 (HER2/neu)-driven murine breast cancer. However, the amplification status and function of GAB2 in the context of amplification remain undefined. In this study, by genomic profiling of 172 breast tumors, and fluorescence in situ hybridization validation in an independent set of 210 scorable cases, we observed focal amplification spanning GAB2 (11q14.1) independent of CCND1 (11q13.2) amplification, consistent with a driver role. Further, small interfering RNA (siRNA)-mediated knockdown of GAB2 in breast cancer lines (SUM52, SUM44PE and MDA468) with GAB2 amplification revealed a dependency on GAB2 for cell proliferation, cell-cycle progression, survival and invasion, likely mediated through altered phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling. GAB2 knockdown also reduced proliferation and survival in a cell line (BT474) with ERBB2 amplification, consistent with the possibility that GAB2 can function downstream of ERBB2. Our studies implicate focal amplification of GAB2 in breast carcinogenesis, and underscore an oncogenic role of scaffolding adapter proteins, and a potential new point of therapeutic intervention.Oncogene ( Keywords: GAB2; DNA amplification; genomic profiling; array-based comparative genomic hybridization; breast cancer; oncogene dependency Breast cancer is the second leading cause of cancer death in women in the United States (Jemal et al., 2007), affecting all races and ethnicities. Breast cancer develops through multiple genetic alterations, including amplification and resultant overexpression of oncogenes. The discovery and characterization of amplified oncogenes informs the understanding of breast cancer pathogenesis, and provides useful biomarkers and therapeutic targets. This is best exemplified by ERBB2 (Her2/neu; 17q12), a receptor tyrosine kinase amplified in 20-30% of breast cancers and the target of molecularly directed therapies, such as trastuzumab (Pegram et al., 2000).The chromosomal region 11q13-q14 is amplified in 15-20% of breast cancers, and the finding of distinct loci amplified independently or in combination suggests the presence of multiple 'driver' oncogenes (Karlseder et al., 1994;Ormandy et al., 2003). Within the proximal (that is, more centromeric) region, cyclin D1 (CCND1; at 11q13.2) has been considered the main driver, promoting G1-to S-phase cell-cycle progression. Other candidate oncogenes frequently co-amplified at 11q13.2 include fibroblast growth factor-3 (also called int-2) and cortactin (EMSI) (Karlseder et al., 1994). More distally, EMSY (at 11q13.5), encoding a binding partner of breast cancer 2, early onset (BRCA2), has been nominated as an amplicon ...